<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4844">
  <stage>Registered</stage>
  <submitdate>18/02/2015</submitdate>
  <approvaldate>18/02/2015</approvaldate>
  <nctid>NCT02374060</nctid>
  <trial_identification>
    <studytitle>PeriOcular and INTravitreal Corticosteroids for Uveitic Macular Edema Trial</studytitle>
    <scientifictitle>PeriOcular and INTravitreal Corticosteroids for Uveitic Macular Edema Trial</scientifictitle>
    <utrn />
    <trialacronym>POINT</trialacronym>
    <secondaryid>1U10EY024527-01</secondaryid>
    <secondaryid>IRB00006139</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Macular Edema</healthcondition>
    <healthcondition>Uveitis</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Eye</conditioncode1>
      <conditioncode2>Diseases / disorders of the eye</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Periocular triamcinolone 40 mg
Treatment: drugs - Intravitreal triamcinolone 4 mg
Treatment: drugs - Dexamethasone intravitreal implant

Active Comparator: Periocular triamcinolone 40mg - Periocular triamcinolone acetonide (Kenalog), 40 mg Initial injection at Week 0
Second injection permitted at Week 8 IF:
Eye does not meet the improvement definition (a 20% decrease in central subfield thickness of the macula) OR eye has a normal central subfield thickness but has cystoid spaces in the 1 mm central subfield OR ME is worse after initial improvement;
IOP of =21 or mm Hg and treatment with =3 IOP-lowering agents;

Active Comparator: Intravitreal triamcinolone 4mg - (preservative-free preparation, Triescence at U.S. clinics; Triesence preferred at non-U.S. clinics but Kenalog allowed) (4 mg) Initial injection at Week 0
Second injection permitted at Week 8 IF:
Eye does not meet the improvement definition (a 20% decrease in central subfield thickness of the macula) OR eye has a normal central subfield thickness but has cystoid spaces in the 1 mm central subfield OR ME is worse after initial improvement;
IOP of =21 or mm Hg and treatment with =3 IOP-lowering agents;

Active Comparator: Dexamethasoneintravitreal implant - Dexamethasone intravitreal implant (Ozurdex) (0.7 mg) Initial injection at Week 0
Second injection permitted at Week 12 IF:
Eye does not meet the improvement definition (a 20% decrease in central subfield thickness of the macula) OR eye has a normal central subfield thickness but has cystoid spaces in the 1 mm central subfield OR ME is worse after initial improvement;
IOP of =21 or mm Hg and treatment with =3 IOP-lowering agents;


Treatment: drugs: Periocular triamcinolone 40 mg
Periocular triamcinolone acetonide, 40 mg injection may be given either by posterior sub-Tenon's approach or by the orbital floor approach, as both appear to have similar efficacy; the approach to the periocular injection will be recorded for analysis if needed.

Treatment: drugs: Intravitreal triamcinolone 4 mg
Intravitreal triamcinolone acetonide, 4 mg injection procedures should be carried out under controlled aseptic conditions which include the use of sterile gloves and a sterile eyelid speculum (or equivalent). Adequate anesthesia and a broad-spectrum microbicide such as betadine, applied to the periocular skin, eyelid and ocular surface are required prior to an intravitreal injection.

Treatment: drugs: Dexamethasone intravitreal implant
 Standard preparation as described for intravitreal injections.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Percent change in central subfield thickness from the baseline OCT measurement - The primary outcome is the percent change in central subfield thickness from the baseline OCT measurement at the 8-week visit. The time point of 8 weeks was chosen for assessment of the primary outcome because it encompasses the window for maximum benefit for all three treatment strategies. The results will be transformed to represent relative change. Assessment of OCT outcomes will be performed by masked readers.</outcome>
      <timepoint>At week 8 visit</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Eye level inclusion criteria - at least one eye must meet all of the following conditions:

          -  Non-infectious anterior, intermediate, posterior or panuveitis; either active or
             inactive uveitis is acceptable;

          -  Macular edema (ME) defined as the presence of central subfield macular thickness
             greater than the normal range for the OCT machine being used, regardless of the
             presence of cysts, as assessed by study ophthalmologist;

          -  Best corrected visual acuity (BCVA) 5/200 or better;

          -  Baseline intraocular pressure &gt; 5 mm Hg and = 21 mm Hg (current use of 3 or fewer
             intraocular pressure-lowering medications and/or prior glaucoma surgery are
             acceptable);

          -  Baseline fluorescein angiogram that is gradable for leakage in the central subfield

          -  Pupillary dilation sufficient to allow OCT testing.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Patient level exclusion criteria:

        -History of infectious uveitis, or of scleritis, keratitis, or infectious endophthalmitis
        in either eye;

        History of central serous retinopathy in either eye;

          -  For women of childbearing potential: pregnancy, breastfeeding, or a positive pregnancy
             test; unwilling to practice an adequate birth control method (abstinence, combination
             barrier and spermicide, or hormonal) for duration of trial;

          -  Use of oral acetazolamide or other systemic carbonic anhydrase inhibitor at baseline;

          -  Oral prednisone dose &gt; 10 mg per day (or of an alternative corticosteroid at a dose
             higher than that equipotent to prednisone 10 mg per day) OR oral prednisone dose = 10
             mg per day that has not been stable for at least 4 weeks(note that if patient is off
             of oral prednisone at baseline (P01 visit), dose stability requirement for past 4
             weeks does not apply);

          -  Systemic immunosuppressive drug therapy that has not been stable for at least 4 weeks;

          -  Known allergy or hypersensitivity to any component of the study drugs;

        Eye level exclusion criteria - at least one eye that meets all inclusion criteria cannot
        have any of the following conditions:

          -  History of severe glaucoma as defined by optic nerve damage (cup/disc ratio of = 0.9
             or any notching of optic nerve to the rim);

          -  Media opacity causing inability to assess fundus or perform OCT;

          -  Presence of an epiretinal membrane noted clinically or by OCT that per the judgment of
             study ophthalmologist may be significant enough to limit improvement of ME (i.e.,
             causing substantial wrinkling of the retinal surface)81;

          -  Torn or ruptured posterior lens capsule;

          -  Presence of silicone oil;

          -  Periocular or intravitreal corticosteroid injection in past 8 weeks;

          -  Injection of dexamethasone intravitreal implant in past 12 weeks;

          -  Placement of fluocinolone acetonide implant (Retisert) in past 3 years;</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/03/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>267</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Suspended</recruitmentstatus>
    <anticipatedlastvisitdate>1/07/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Royal Victorian Eye &amp; Ear Hospital - East Melbourne</hospital>
    <postcode> - East Melbourne</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Iowa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>JHSPH Center for Clinical Trials</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Government body</othercollaboratortype>
      <othercollaboratorname>National Eye Institute (NEI)</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>To evaluate the relative efficacy of three commonly utilized regional corticosteroids for the
      regional treatment of uveitic macular edema: periocular triamcinolone acetonide; intravitreal
      triamcinolone acetonide; intravitreal dexamethasone implant. The primary efficacy measure
      will be percent change in central subfield thickness as measured by OCT at 8 weeks.
      Participants will continue in the study for 24 weeks in order to evaluate relative effects of
      the 3 treatment strategies on the duration of treatment effects, requirement for additional
      injections, and adverse effects.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02374060</trialwebsite>
    <publication>Okhravi N, Lightman S. Cystoid macular edema in uveitis. Ocul Immunol Inflamm. 2003 Mar;11(1):29-38. Review.
Lardenoye CW, van Kooij B, Rothova A. Impact of macular edema on visual acuity in uveitis. Ophthalmology. 2006 Aug;113(8):1446-9.
Multicenter Uveitis Steroid Treatment Trial Research Group, Kempen JH, Altaweel MM, Holbrook JT, Jabs DA, Sugar EA. The multicenter uveitis steroid treatment trial: rationale, design, and baseline characteristics. Am J Ophthalmol. 2010 Apr;149(4):550-561.e10. doi: 10.1016/j.ajo.2009.11.019. Epub 2010 Jan 25.
Kempen JH, Sugar EA, Jaffe GJ, Acharya NR, Dunn JP, Elner SG, Lightman SL, Thorne JE, Vitale AT, Altaweel MM; Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group. Fluorescein angiography versus optical coherence tomography for diagnosis of uveitic macular edema. Ophthalmology. 2013 Sep;120(9):1852-9. doi: 10.1016/j.ophtha.2013.01.069. Epub 2013 May 21.
Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group, Kempen JH, Altaweel MM, Holbrook JT, Jabs DA, Louis TA, Sugar EA, Thorne JE. Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial. Ophthalmology. 2011 Oct;118(10):1916-26. doi: 10.1016/j.ophtha.2011.07.027. Epub 2011 Aug 15. Erratum in: Ophthalmology. 2012 Feb;119(2):212.
Dong Z, Namba K, Kitaichi N, Goda C, Kitamura M, Ohno S. Efficacy and complications of intravitreal injection of triamcinolone acetonide for refractory cystoid macular edema associated with intraocular inflammation. Jpn J Ophthalmol. 2008 Sep-Oct;52(5):374-9. doi: 10.1007/s10384-008-0574-2. Epub 2008 Nov 11.
Rothova A, Suttorp-van Schulten MS, Frits Treffers W, Kijlstra A. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol. 1996 Apr;80(4):332-6.
Estafanous MF, Lowder CY, Kaiser PK. Patterns of macular edema in uveitis patients. Ophthalmology. 2005 Feb;112(2):360; author reply 360-1.
Markomichelakis NN, Halkiadakis I, Pantelia E, Peponis V, Patelis A, Theodossiadis P, Theodossiadis G. Patterns of macular edema in patients with uveitis: qualitative and quantitative assessment using optical coherence tomography. Ophthalmology. 2004 May;111(5):946-53.
Martidis A, Duker JS, Puliafito CA. Intravitreal triamcinolone for refractory cystoid macular edema secondary to birdshot retinochoroidopathy. Arch Ophthalmol. 2001 Sep;119(9):1380-3.
Ossewaarde-van Norel A, Rothova A. Clinical review: Update on treatment of inflammatory macular edema. Ocul Immunol Inflamm. 2011 Feb;19(1):75-83. doi: 10.3109/09273948.2010.509530. Epub 2010 Oct 31. Review.
Thorne JE, Daniel E, Jabs DA, Kedhar SR, Peters GB, Dunn JP. Smoking as a risk factor for cystoid macular edema complicating intermediate uveitis. Am J Ophthalmol. 2008 May;145(5):841-6. doi: 10.1016/j.ajo.2007.12.032. Epub 2008 Mar 5.
Lin P, Loh AR, Margolis TP, Acharya NR. Cigarette smoking as a risk factor for uveitis. Ophthalmology. 2010 Mar;117(3):585-90. doi: 10.1016/j.ophtha.2009.08.011. Epub 2009 Dec 24.
Hazirolan D, Pleyer U. Think global--act local: intravitreal drug delivery systems in chronic noninfectious uveitis. Ophthalmic Res. 2013;49(2):59-65. doi: 10.1159/000345477. Epub 2012 Dec 15. Review.
Modorati G, Miserocchi E. Intravitreal injection therapy in the treatment of noninfectious uveitis. Dev Ophthalmol. 2012;51:110-21. doi: 10.1159/000336471. Epub 2012 Apr 17. Review.
Sallam A, Taylor SR, Lightman S. Review and update of intraocular therapy in noninfectious uveitis. Curr Opin Ophthalmol. 2011 Nov;22(6):517-22. doi: 10.1097/ICU.0b013e32834bbd68. Review.
Lobo AM, Sobrin L, Papaliodis GN. Drug delivery options for the treatment of ocular inflammation. Semin Ophthalmol. 2010 Sep-Nov;25(5-6):283-8. doi: 10.3109/08820538.2010.518522. Review.
Sallam A, Comer RM, Chang JH, Grigg JR, Andrews R, McCluskey PJ, Lightman S. Short-term safety and efficacy of intravitreal triamcinolone acetonide for uveitic macular edema in children. Arch Ophthalmol. 2008 Feb;126(2):200-5. doi: 10.1001/archophthalmol.2007.59.
Beer PM, Bakri SJ, Singh RJ, Liu W, Peters GB 3rd, Miller M. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology. 2003 Apr;110(4):681-6.
Tranos P, Scott R, Zambarakji H, Ayliffe W, Pavesio C, Charteris DG. The effect of pars plana vitrectomy on cystoid macular oedema associated with chronic uveitis: a randomised, controlled pilot study. Br J Ophthalmol. 2006 Sep;90(9):1107-10. Epub 2006 May 24. Erratum in: Br J Ophthalmol. 2007 Aug;91(8):1097. Zambarajki, H [corrected to Zambarakji, H].
Becker MD, Harsch N, Zierhut M, Davis JL, Holz FG. [Therapeutic vitrectomy in uveitis: current status and recommendations]. Ophthalmologe. 2003 Oct;100(10):787-95. Review. German.
Stahn C, Buttgereit F. Genomic and nongenomic effects of glucocorticoids. Nat Clin Pract Rheumatol. 2008 Oct;4(10):525-33. doi: 10.1038/ncprheum0898. Epub 2008 Sep 2. Review.
Edelman JL, Lutz D, Castro MR. Corticosteroids inhibit VEGF-induced vascular leakage in a rabbit model of blood-retinal and blood-aqueous barrier breakdown. Exp Eye Res. 2005 Feb;80(2):249-58.
Vinores SA, Chan CC, Vinores MA, Matteson DM, Chen YS, Klein DA, Shi A, Ozaki H, Campochiaro PA. Increased vascular endothelial growth factor (VEGF) and transforming growth factor beta (TGFbeta) in experimental autoimmune uveoretinitis: upregulation of VEGF without neovascularization. J Neuroimmunol. 1998 Aug 14;89(1-2):43-50.
Fine HF, Baffi J, Reed GF, Csaky KG, Nussenblatt RB. Aqueous humor and plasma vascular endothelial growth factor in uveitis-associated cystoid macular edema. Am J Ophthalmol. 2001 Nov;132(5):794-6.
Weiss K, Steinbrugger I, Weger M, Ardjomand N, Maier R, Wegscheider BJ, Wedrich A, El-Shabrawi Y. Intravitreal VEGF levels in uveitis patients and treatment of uveitic macular oedema with intravitreal bevacizumab. Eye (Lond). 2009 Sep;23(9):1812-8. doi: 10.1038/eye.2008.388. Epub 2009 Jan 23.
van Kooij B, Rothova A, Rijkers GT, de Groot-Mijnes JD. Distinct cytokine and chemokine profiles in the aqueous of patients with uveitis and cystoid macular edema. Am J Ophthalmol. 2006 Jul;142(1):192-4.
Cohen T, Nahari D, Cerem LW, Neufeld G, Levi BZ. Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem. 1996 Jan 12;271(2):736-41.
Jennings T, Rusin MM, Tessler HH, Cunha-Vaz JG. Posterior sub-Tenon's injections of corticosteroids in uveitis patients with cystoid macular edema. Jpn J Ophthalmol. 1988;32(4):385-91.
Helm CJ, Holland GN. The effects of posterior subtenon injection of triamcinolone acetonide in patients with intermediate uveitis. Am J Ophthalmol. 1995 Jul;120(1):55-64.
Antcliff RJ, Spalton DJ, Stanford MR, Graham EM, ffytche TJ, Marshall J. Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study. Ophthalmology. 2001 Apr;108(4):765-72.
Karacorlu M, Mudun B, Ozdemir H, Karacorlu SA, Burumcek E. Intravitreal triamcinolone acetonide for the treatment of cystoid macular edema secondary to Behçet disease. Am J Ophthalmol. 2004 Aug;138(2):289-91.
Kok H, Lau C, Maycock N, McCluskey P, Lightman S. Outcome of intravitreal triamcinolone in uveitis. Ophthalmology. 2005 Nov;112(11):1916.e1-7. Epub 2005 Sep 19.
Young S, Larkin G, Branley M, Lightman S. Safety and efficacy of intravitreal triamcinolone for cystoid macular oedema in uveitis. Clin Exp Ophthalmol. 2001 Feb;29(1):2-6.
Sørensen TL, Haamann P, Villumsen J, Larsen M. Intravitreal triamcinolone for macular oedema: efficacy in relation to aetiology. Acta Ophthalmol Scand. 2005 Feb;83(1):67-70.
Hogewind BF, Zijlstra C, Klevering BJ, Hoyng CB. Intravitreal triamcinolone for the treatment of refractory macular edema in idiopathic intermediate or posterior uveitis. Eur J Ophthalmol. 2008 May-Jun;18(3):429-34.
Androudi S, Letko E, Meniconi M, Papadaki T, Ahmed M, Foster CS. Safety and efficacy of intravitreal triamcinolone acetonide for uveitic macular edema. Ocul Immunol Inflamm. 2005 Apr-Jun;13(2-3):205-12.
Oueghlani E, Pavésio CE. Intravitreal triamcinolone injection for unresponsive cystoid macular oedema in probable Behçet's disease as an additional therapy. Klin Monbl Augenheilkd. 2008 May;225(5):497-9. doi: 10.1055/s-2008-1027351.
Choudhry S, Ghosh S. Intravitreal and posterior subtenon triamcinolone acetonide in idiopathic bilateral uveitic macular oedema. Clin Exp Ophthalmol. 2007 Nov;35(8):713-8.
Roesel M, Gutfleisch M, Heinz C, Heimes B, Zurek-Imhoff B, Heiligenhaus A. Intravitreal and orbital floor triamcinolone acetonide injections in noninfectious uveitis: a comparative study. Ophthalmic Res. 2009;42(2):81-6. doi: 10.1159/000220600. Epub 2009 May 27.
Thach AB, Dugel PU, Flindall RJ, Sipperley JO, Sneed SR. A comparison of retrobulbar versus sub-Tenon's corticosteroid therapy for cystoid macular edema refractory to topical medications. Ophthalmology. 1997 Dec;104(12):2003-8.
Ferrante P, Ramsey A, Bunce C, Lightman S. Clinical trial to compare efficacy and side-effects of injection of posterior sub-Tenon triamcinolone versus orbital floor methylprednisolone in the management of posterior uveitis. Clin Exp Ophthalmol. 2004 Dec;32(6):563-8.
Venkatesh P, Kumar CS, Abbas Z, Garg S. Comparison of the efficacy and safety of different methods of posterior subtenon injection. Ocul Immunol Inflamm. 2008 Sep-Oct;16(5):217-23. doi: 10.1080/09273940802209153.
Byun YS, Park YH. Complications and safety profile of posterior subtenon injection of triamcinolone acetonide. J Ocul Pharmacol Ther. 2009 Apr;25(2):159-62. doi: 10.1089/jop.2008.0087.
Leder HA, Jabs DA, Galor A, Dunn JP, Thorne JE. Periocular triamcinolone acetonide injections for cystoid macular edema complicating noninfectious uveitis. Am J Ophthalmol. 2011 Sep;152(3):441-448.e2. doi: 10.1016/j.ajo.2011.02.009. Epub 2011 Jun 8.
Hirano Y, Ito T, Nozaki M, Yasukawa T, Sakurai E, Yoshida M, Ogura Y. Intraocular pressure elevation following triamcinolone acetonide administration as related to administration routes. Jpn J Ophthalmol. 2009 Sep;53(5):519-22. doi: 10.1007/s10384-009-0692-5. Epub 2009 Oct 22.
Jonas JB, Degenring RF, Kreissig I, Akkoyun I, Kamppeter BA. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmology. 2005 Apr;112(4):593-8.
Smithen LM, Ober MD, Maranan L, Spaide RF. Intravitreal triamcinolone acetonide and intraocular pressure. Am J Ophthalmol. 2004 Nov;138(5):740-3.
Gillies MC, Simpson JM, Billson FA, Luo W, Penfold P, Chua W, Mitchell P, Zhu M, Hunyor AB. Safety of an intravitreal injection of triamcinolone: results from a randomized clinical trial. Arch Ophthalmol. 2004 Mar;122(3):336-40.
van Kooij B, Rothova A, de Vries P. The pros and cons of intravitreal triamcinolone injections for uveitis and inflammatory cystoid macular edema. Ocul Immunol Inflamm. 2006 Apr;14(2):73-85. Review.
Maca SM, Abela-Formanek C, Kiss CG, Sacu SG, Benesch T, Barisani-Asenbauer T. Intravitreal triamcinolone for persistent cystoid macular oedema in eyes with quiescent uveitis. Clin Exp Ophthalmol. 2009 May;37(4):389-96. doi: 10.1111/j.1442-9071.2009.02033.x.
Gillies MC, Islam FM, Zhu M, Larsson J, Wong TY. Efficacy and safety of multiple intravitreal triamcinolone injections for refractory diabetic macular oedema. Br J Ophthalmol. 2007 Oct;91(10):1323-6. Epub 2007 Apr 3.
Roth DB, Verma V, Realini T, Prenner JL, Feuer WJ, Fechtner RD. Long-term incidence and timing of intraocular hypertension after intravitreal triamcinolone acetonide injection. Ophthalmology. 2009 Mar;116(3):455-60. doi: 10.1016/j.ophtha.2008.10.002. Epub 2009 Jan 20.
Das-Bhaumik RG, Jones NP. Low-dose intraocular triamcinolone injection for intractable macular oedema and inflammation in patients with uveitis. Eye (Lond). 2006 Aug;20(8):934-7. Epub 2005 Aug 12.
Jonas JB, Schlichtenbrede F. Visual acuity and intraocular pressure after high-dose intravitreal triamcinolone acetonide in selected ocular diseases. Eye (Lond). 2008 Jul;22(7):869-73. Epub 2007 Feb 16. Review.
Angunawela RI, Heatley CJ, Williamson TH, Spalton DJ, Graham EM, Antcliffe RJ, Stanford MR. Intravitreal triamcinalone acetonide for refractory uveitic cystoid macular oedema: longterm management and outcome. Acta Ophthalmol Scand. 2005 Oct;83(5):595-9.
Sallam A, Taylor SR, Habot-Wilner Z, Elgohary M, Do HH, McCluskey P, Lightman S. Repeat intravitreal triamcinolone acetonide injections in uveitic macular oedema. Acta Ophthalmol. 2012 Jun;90(4):e323-5. doi: 10.1111/j.1755-3768.2011.02247.x. Epub 2011 Sep 13.
Menezo V, Lau C, Comer M, Lightman S. Clinical outcome of chronic immunosuppression in patients with non-infectious uveitis. Clin Exp Ophthalmol. 2005 Feb;33(1):16-21.
Habot-Wilner Z, Sallam A, Pacheco PA, Do HH, McCluskey P, Lightman S. Intravitreal triamcinolone acetonide as adjunctive treatment with systemic therapy for uveitic macular edema. Eur J Ophthalmol. 2011;21 Suppl 6:S56-61. doi: 10.5301/EJO.2010.6062.
da Silva GR, da Silva Cunha A Jr, Ayres E, Oréfice RL. Effect of the macromolecular architecture of biodegradable polyurethanes on the controlled delivery of ocular drugs. J Mater Sci Mater Med. 2009 Feb;20(2):481-7. doi: 10.1007/s10856-008-3607-y. Epub 2008 Oct 14.
Kuppermann BD, Blumenkranz MS, Haller JA, Williams GA, Weinberg DV, Chou C, Whitcup SM; Dexamethasone DDS Phase II Study Group. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol. 2007 Mar;125(3):309-17.
Williams GA, Haller JA, Kuppermann BD, Blumenkranz MS, Weinberg DV, Chou C, Whitcup SM; Dexamethasone DDS Phase II Study Group. Dexamethasone posterior-segment drug delivery system in the treatment of macular edema resulting from uveitis or Irvine-Gass syndrome. Am J Ophthalmol. 2009 Jun;147(6):1048-54, 1054.e1-2. doi: 10.1016/j.ajo.2008.12.033. Epub 2009 Mar 9.
Herrero-Vanrell R, Cardillo JA, Kuppermann BD. Clinical applications of the sustained-release dexamethasone implant for treatment of macular edema. Clin Ophthalmol. 2011;5:139-46. doi: 10.2147/OPTH.S15783. Epub 2011 Feb 1.
Hunter RS, Lobo AM. Dexamethasone intravitreal implant for the treatment of noninfectious uveitis. Clin Ophthalmol. 2011;5:1613-21. doi: 10.2147/OPTH.S17419. Epub 2011 Nov 11.
London NJ, Chiang A, Haller JA. The dexamethasone drug delivery system: indications and evidence. Adv Ther. 2011 May;28(5):351-66. doi: 10.1007/s12325-011-0019-z. Epub 2011 Mar 12. Review. Erratum in: Adv Ther. 2013 Jun;30(6):644.
Saraiya NV, Goldstein DA. Dexamethasone for ocular inflammation. Expert Opin Pharmacother. 2011 May;12(7):1127-31. doi: 10.1517/14656566.2011.571209. Epub 2011 Apr 2. Review.
Lowder C, Belfort R Jr, Lightman S, Foster CS, Robinson MR, Schiffman RM, Li XY, Cui H, Whitcup SM; Ozurdex HURON Study Group. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol. 2011 May;129(5):545-53. doi: 10.1001/archophthalmol.2010.339. Epub 2011 Jan 10.
Myung JS, Aaker GD, Kiss S. Treatment of noninfectious posterior uveitis with dexamethasone intravitreal implant. Clin Ophthalmol. 2010 Dec 6;4:1423-6. doi: 10.2147/OPTH.S15696.
Miserocchi E, Modorati G, Pastore MR, Bandello F. Dexamethasone intravitreal implant: an effective adjunctive treatment for recalcitrant noninfectious uveitis. Ophthalmologica. 2012;228(4):229-33. doi: 10.1159/000343060. Epub 2012 Oct 3.
Querques L, Querques G, Lattanzio R, Gigante SR, Del Turco C, Corradetti G, Cascavilla ML, Bandello F. Repeated intravitreal dexamethasone implant (Ozurdex®) for retinal vein occlusion. Ophthalmologica. 2013;229(1):21-5. doi: 10.1159/000342160. Epub 2012 Sep 19.
Audren F, Tod M, Massin P, Benosman R, Haouchine B, Erginay A, Caulin C, Gaudric A, Bergmann JF. Pharmacokinetic-pharmacodynamic modeling of the effect of triamcinolone acetonide on central macular thickness in patients with diabetic macular edema. Invest Ophthalmol Vis Sci. 2004 Oct;45(10):3435-41.
Nussenblatt RB, Kaufman SC, Palestine AG, Davis MD, Ferris FL 3rd. Macular thickening and visual acuity. Measurement in patients with cystoid macular edema. Ophthalmology. 1987 Sep;94(9):1134-9.
Sugar EA, Jabs DA, Altaweel MM, Lightman S, Acharya N, Vitale AT, Thorne JE; Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group. Identifying a clinically meaningful threshold for change in uveitic macular edema evaluated by optical coherence tomography. Am J Ophthalmol. 2011 Dec;152(6):1044-1052.e5. doi: 10.1016/j.ajo.2011.05.028. Epub 2011 Sep 8.
Ferris FL 3rd, Kassoff A, Bresnick GH, Bailey I. New visual acuity charts for clinical research. Am J Ophthalmol. 1982 Jul;94(1):91-6.
KIMURA SJ, THYGESON P, HOGAN MJ. Signs and symptoms of uveitis. II. Classification of the posterior manifestations of uveitis. Am J Ophthalmol. 1959 May;47(5 Pt 2):171-6.
Nussenblatt R, Whitcup, SM, Palestine, AG. Uveitis: Fundamentals and Clinical Practice. 2 ed. St. Louis: Mosby; 1996.
Nussenblatt RB, Palestine AG, Chan CC, Roberge F. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology. 1985 Apr;92(4):467-71.
Jabs DA, Nussenblatt RB, Rosenbaum JT; Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005 Sep;140(3):509-16. Review.
Age-Related Eye Disease Study Research Group. The age-related eye disease study (AREDS) system for classifying cataracts from photographs: AREDS report no. 4. Am J Ophthalmol. 2001 Feb;131(2):167-75.
Lehpamer B, Moshier E, Pahk P, Goldberg N, Ackert J, Godbold J, Jabs DA. Epiretinal membranes in uveitic macular edema: effect on vision and response to therapy. Am J Ophthalmol. 2014 May;157(5):1048-55. doi: 10.1016/j.ajo.2014.01.020. Epub 2014 Jan 30.
Ozurdex (package insert). Allergan, Inc. Irvine, CA 92612: 2013.
Triesence (package insert). Alcon. Fort Worth, TX 76134: 2008.
LUCENTIS (ranibizumab injection) (Package Insert). Genentech Inc. South San Francisco, CA 94080: February 2013.
Day S, Acquah K, Mruthyunjaya P, Grossman DS, Lee PP, Sloan FA. Ocular complications after anti-vascular endothelial growth factor therapy in Medicare patients with age-related macular degeneration. Am J Ophthalmol. 2011 Aug;152(2):266-72. doi: 10.1016/j.ajo.2011.01.053. Epub 2011 Jun 12.
Manatunga AK, Chen S. Sample size estimation for survival outcomes in cluster-randomized studies with small cluster sizes. Biometrics. 2000 Jun;56(2):616-21.
Ferris FL 3rd, Miller KM, Glassman AR, Beck RW; Diabetic Retinopathy Clinical Research Network. A proposed method of logarithmic transformation of optical coherence tomography data for use in clinical research. Ophthalmology. 2010 Aug;117(8):1512-6. doi: 10.1016/j.ophtha.2009.12.014. Epub 2010 Apr 3.
Diabetic Retinopathy Clinical Research Network, Krzystolik MG, Strauber SF, Aiello LP, Beck RW, Berger BB, Bressler NM, Browning DJ, Chambers RB, Danis RP, Davis MD, Glassman AR, Gonzalez VH, Greenberg PB, Gross JG, Kim JE, Kollman C. Reproducibility of macular thickness and volume using Zeiss optical coherence tomography in patients with diabetic macular edema. Ophthalmology. 2007 Aug;114(8):1520-5. Epub 2007 Mar 13.
Lehpamer B, Moshier E, Goldberg N, Ackert J, Godbold J, Jabs DA. Subretinal fluid in uveitic macular edema: effect on vision and response to therapy. Am J Ophthalmol. 2013 Jan;155(1):143-9. doi: 10.1016/j.ajo.2012.06.028. Epub 2012 Sep 27.
Diggle P HP, Liang K-Y, Zeger S. Analysis of Longitudinal Data. New York: Oxford University Press Inc.; 2002.
Gutierrez R. Parametric frailty and shared frailty survival models. The Stata Journal. 2002;2(1):22-44.
Tarwater PM, Mellors J, Gore ME, Margolick JB, Phair J, Detels R, Muñoz A. Methods to assess population effectiveness of therapies in human immunodeficiency virus incident and prevalent cohorts. Am J Epidemiol. 2001 Oct 1;154(7):675-81.
Keene ON, Jones MR, Lane PW, Anderson J. Analysis of exacerbation rates in asthma and chronic obstructive pulmonary disease: example from the TRISTAN study. Pharm Stat. 2007 Apr-Jun;6(2):89-97.
Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM. Statistics in medicine--reporting of subgroup analyses in clinical trials. N Engl J Med. 2007 Nov 22;357(21):2189-94.
Daniels MJ HJ. Missing Data in Longitudinal Studies: Strategies for Bayesian Modeling and Sensitivity Analysis. Boca Raton: Chapman &amp; Hall/CRC; 2008.
Little RJA RD. Statistical Analysis with Missing Data. 2nd ed. New York: John Wiley &amp; Sons; 2002.
</publication>
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Douglas A Jabs, MD, MBA</name>
      <address>Icahn School of Medicine, Noutn Sinai, New York, NY</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>